Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 214 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males

NCT03792477
Conditions
Hypogonadism
Interventions
Test formulation, Reference formulation
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
DeLand, Florida • Miami, Florida
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Oral Androgens in Man-4: (Short Title: Oral T-4)

NCT00399165
Conditions
Contraception
Interventions
Testosterone Enanthate, Dutasteride, placebo sesame oil
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NCT00805207
Conditions
Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions
Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
Drug · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries, Central Nervous System Diseases, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions
Testosterone Enanthate, Finasteride, Placebo injection, Placebo pill
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Completed Phase 4 Interventional Accepts healthy volunteers

The Role of 5-alpha Reductase in Mediating Testosterone Actions

NCT00493987
Conditions
Healthy
Interventions
Testosterone Enanthate, Dutasteride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Replacement Study

NCT00957528
Conditions
Hypogonadism
Interventions
Testosterone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Galveston, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men

NCT00365794
Conditions
Aging, Obesity, Insulin Resistance, Hypogonadism
Interventions
Topical testosterone gel 10 g/day
Drug
Lead sponsor
University of Southern California
Other
Eligibility
60 Years to 90 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 1Phase 2 Interventional Results available

Testosterone Treatment for Multiple Sclerosis

NCT00405353
Conditions
Multiple Sclerosis
Interventions
Androgel 10 grams of gel containing 100 mg of testosterone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Muscle Atrophy, ACL Reconstruction, Trauma, Osteoarthritis
Interventions
Testosterone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Cancer
Interventions
Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Diego, California
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Columbus, Ohio
Conditions
Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
Interventions
Aveed Injectable Product, Fortesta, Testim
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Menopause
Interventions
esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Compromised Microcirculation in Women With Polycystic Ovary Syndrome

NCT00757185
Conditions
Polycystic Ovary Syndrome
Interventions
ganirelix acetate, methyl testosterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Hypogonadism
Interventions
Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • San Antonio, Texas
Conditions
Hypogonadism
Interventions
Testosterone undecanoate, Testosterone enanthate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Completed Phase 4 Interventional Accepts healthy volunteers

Hormones and Decision Making

NCT04865562
Conditions
Dyssocial Behavior
Interventions
testosterone propionate, 0.5% cholorbutanol, saline
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Conditions
Hypogonadism
Interventions
Testosterone MD-Lotion
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Tuscon, Arizona • Burbank, California • New Britain, Connecticut + 1 more
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

NCT04327934
Conditions
Polycystic Ovary Syndrome, Hypertension
Interventions
GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Stress Urinary Incontinence, Menopause
Interventions
Testosterone cypionate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Oral Testosterone for the Treatment of Hypogonadism

NCT01717768
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California